Trial Profile
Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Midazolam (Primary) ; Raltegravir (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 01 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Apr 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 18 Dec 2008 New trial record.